160 related articles for article (PubMed ID: 19240653)
21. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.
Chua KN; Kong LR; Sim WJ; Ng HC; Ong WR; Thiery JP; Huynh H; Goh BC
Oncotarget; 2015 Oct; 6(30):29991-30005. PubMed ID: 26358373
[TBL] [Abstract][Full Text] [Related]
22. Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer.
Lin SY; Chang HH; Lai YH; Lin CH; Chen MH; Chang GC; Tsai MF; Chen JJ
PLoS One; 2015; 10(5):e0123305. PubMed ID: 25955608
[TBL] [Abstract][Full Text] [Related]
23. Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
Jones RJ; Young O; Renshaw L; Jacobs V; Fennell M; Marshall A; Green TP; Elvin P; Womack C; Clack G; Dixon JM
Breast Cancer Res Treat; 2009 Mar; 114(2):211-21. PubMed ID: 18409068
[TBL] [Abstract][Full Text] [Related]
24. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
Yang JC; Ok JH; Busby JE; Borowsky AD; Kung HJ; Evans CP
Cancer Res; 2009 Jan; 69(1):151-60. PubMed ID: 19117998
[TBL] [Abstract][Full Text] [Related]
25. Silymarin suppresses the PGE2 -induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways.
Woo SM; Min KJ; Chae IG; Chun KS; Kwon TK
Mol Carcinog; 2015 Mar; 54(3):216-28. PubMed ID: 24127286
[TBL] [Abstract][Full Text] [Related]
26. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
[TBL] [Abstract][Full Text] [Related]
27. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
28. miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.
Jin J; Sun Z; Yang F; Tang L; Chen W; Guan X
Arch Biochem Biophys; 2018 May; 645():54-60. PubMed ID: 29550144
[TBL] [Abstract][Full Text] [Related]
29. Kinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
Azijli K; Yuvaraj S; Peppelenbosch MP; Würdinger T; Dekker H; Joore J; van Dijk E; Quax WJ; Peters GJ; de Jong S; Kruyt FA
J Cell Sci; 2012 Oct; 125(Pt 19):4651-61. PubMed ID: 22797920
[TBL] [Abstract][Full Text] [Related]
30. Inhibition by platelet-activating factor of Src- and hepatocyte growth factor-dependent invasiveness of intestinal and kidney epithelial cells. Phosphatidylinositol 3'-kinase is a critical mediator of tumor invasion.
Kotelevets L; Noë V; Bruyneel E; Myssiakine E; Chastre E; Mareel M; Gespach C
J Biol Chem; 1998 Jun; 273(23):14138-45. PubMed ID: 9603913
[TBL] [Abstract][Full Text] [Related]
31. Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
Xiong J; Wu JS; Mao SS; Yu XN; Huang XX
Oncol Rep; 2016 Sep; 36(3):1483-90. PubMed ID: 27460949
[TBL] [Abstract][Full Text] [Related]
32. A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
Serrels B; Serrels A; Mason SM; Baldeschi C; Ashton GH; Canel M; Mackintosh LJ; Doyle B; Green TP; Frame MC; Sansom OJ; Brunton VG
Carcinogenesis; 2009 Feb; 30(2):249-57. PubMed ID: 19060248
[TBL] [Abstract][Full Text] [Related]
33. Lipopolysaccharide induces VCAM-1 expression and neutrophil adhesion to human tracheal smooth muscle cells: involvement of Src/EGFR/PI3-K/Akt pathway.
Lin WN; Luo SF; Wu CB; Lin CC; Yang CM
Toxicol Appl Pharmacol; 2008 Apr; 228(2):256-68. PubMed ID: 18182168
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of Src activation with cardiotoxin III blocks migration and invasion of MDA-MB-231 cells.
Tsai PC; Chu CL; Chiu CC; Chang LS; Lin SR
Toxicon; 2013 Nov; 74():56-67. PubMed ID: 23933586
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
36. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Fang H; Jin J; Huang D; Yang F; Guan X
Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
[TBL] [Abstract][Full Text] [Related]
37. Expression and functional role of CRIPTO-1 in cutaneous melanoma.
De Luca A; Lamura L; Strizzi L; Roma C; D'Antonio A; Margaryan N; Pirozzi G; Hsu MY; Botti G; Mari E; Hendrix MJ; Salomon DS; Normanno N
Br J Cancer; 2011 Sep; 105(7):1030-8. PubMed ID: 21863025
[TBL] [Abstract][Full Text] [Related]
38. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
[TBL] [Abstract][Full Text] [Related]
39. Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Morrow CJ; Ghattas M; Smith C; Bönisch H; Bryce RA; Hickinson DM; Green TP; Dive C
Cancer Res; 2010 Jul; 70(14):5931-41. PubMed ID: 20551056
[TBL] [Abstract][Full Text] [Related]
40. Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.
Kaufman AC; Salazar SV; Haas LT; Yang J; Kostylev MA; Jeng AT; Robinson SA; Gunther EC; van Dyck CH; Nygaard HB; Strittmatter SM
Ann Neurol; 2015 Jun; 77(6):953-71. PubMed ID: 25707991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]